HTML Microdata document

This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n17	http://www.rxlist.com/cgi/generic3/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n26	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/chebi/
foaf	http://xmlns.com/foaf/0.1/
n15	http://linked.opendata.cz/resource/mesh/concept/
n4	http://linked.opendata.cz/resource/drugbank/company/
n5	http://linked.opendata.cz/resource/drugbank/dosage/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/wikipedia/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/pharmgkb/
n16	http://bio2rdf.org/drugbank:
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/bindingdb/
n28	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/pubchem-compound/
adms	http://www.w3.org/ns/adms#
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/pubchem-substance/
n31	http://linked.opendata.cz/resource/drugbank/patent/
n13	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/drugbank/
n29	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/iuphar/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n11	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n14	http://linked.opendata.cz/ontology/mesh/
n25	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/guide-to-pharmacology/
n3	http://linked.opendata.cz/ontology/drugbank/
n7	http://www.drugs.com/cdi/
n30	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/national-drug-code-directory/
n10	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n9	http://linked.opendata.cz/resource/atc/
n27	http://linked.opendata.cz/resource/drugbank/drug/DB00969/identifier/chemspider/
n8	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00969
rdf:type: n3:Drug
n3:description: Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.
n3:dosage: n5:271B45F5-363D-11E5-9242-09173F13E4C5 n5:271B45F6-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Andresen V, Hollerbach S: Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27(5):283-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15061683 # Camilleri M: Pharmacology and clinical experience with alosetron. Expert Opin Investig Drugs. 2000 Jan;9(1):147-59. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060667 # Mayer EA, Bradesi S: Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14596662 # Rahimi R, Nikfar S, Abdollahi M: Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008 May;30(5):884-901. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18555935 # Lewis JH: Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20136586
n3:group: withdrawn approved
n3:halfLife: 1.5 hours
n3:indication: Only for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.
n3:manufacturer: n4:271B45F2-363D-11E5-9242-09173F13E4C5
owl:sameAs: n13:DB00969 n16:DB00969
dcterms:title: Alosetron
adms:identifier: n19:PA164745502 n20:Alosetron n22:50131429 n23:46506274 n24:DB00969 n25:2296 n26:253342 n27:2015 n28:2099 n29:2296 n30:0173-0738-00
n3:mechanismOfAction: Alosetron is a potent and selective 5-HT3 receptor antagonist. 5-HT3 receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT3 receptor antagonists such as alosetron inhibit activation of non-selective cation channels which results in the modulation of serotonin-sensitive GI motor and sensory processes.
n3:packager: n4:271B45F0-363D-11E5-9242-09173F13E4C5 n4:271B45F1-363D-11E5-9242-09173F13E4C5
n3:patent: n31:5360800
n3:routeOfElimination: Renal elimination of unchanged alosetron accounts for only 6% of the dose. Alosetron is extensively metabolized in humans.
n3:synonym: 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one
n3:volumeOfDistribution: * 65 to 95 L
n3:foodInteraction: Take without regard to meals. Absorption is decreased by about 25% when taken with meals.
n3:proteinBinding: 82%
n3:salt
n3:synthesisReference: Buchi Reddy REGURI, Sampathkumar UPPARAPALLI, Nilam SAHU, Karunakara Rao JAVVAJI, Brahma Reddy GADE, "PROCESS FOR THE PREPARATION OF ALOSETRON." U.S. Patent US20120178937, issued July 12, 2012.
n14:hasConcept: n15:M0240025
foaf:page: n7:alosetron.html n17:alosetron.htm
n3:IUPAC-Name: n10:271B45FB-363D-11E5-9242-09173F13E4C5
n3:InChI: n10:271B4601-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n10:271B4600-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n10:271B45FD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n10:271B45FE-363D-11E5-9242-09173F13E4C5
n3:SMILES: n10:271B45FF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n10:271B45F9-363D-11E5-9242-09173F13E4C5
n3:logP: n10:271B45FA-363D-11E5-9242-09173F13E4C5 n10:271B45F7-363D-11E5-9242-09173F13E4C5 n10:271B4611-363D-11E5-9242-09173F13E4C5
n3:logS: n10:271B45F8-363D-11E5-9242-09173F13E4C5
n8:hasATCCode: n9:A03AE01
n3:H-Bond-Acceptor-Count: n10:271B4607-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n10:271B4608-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n10:271B4602-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n10:271B4603-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n10:271B4605-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n10:271B4604-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n10:271B4606-363D-11E5-9242-09173F13E4C5
n3:absorption: 50-60 %
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 122852-42-0
n3:clearance: * 600 mL/min
n3:containedIn: n11:271B45F3-363D-11E5-9242-09173F13E4C5 n11:271B45F4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n10:271B460D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n10:271B460F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n10:271B4610-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n10:271B460C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n10:271B460B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n10:271B460E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n10:271B45FC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n10:271B4609-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n10:271B460A-363D-11E5-9242-09173F13E4C5